TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05320198: RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anem

Sponsor: Disc Medicine, Inc · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,307,825

Rescue Site Savings

+$3,489,675

Unlock Full NCT05320198 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05320198 Rescue Dossier →